Compare KRG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRG | RYTM |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | 2004 | 2017 |
| Metric | KRG | RYTM |
|---|---|---|
| Price | $24.63 | $86.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $25.82 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.5M | 985.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | ★ 6750.00 | 28.34 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $844,365,000.00 | N/A |
| Revenue This Year | N/A | $55.17 |
| Revenue Next Year | N/A | $95.98 |
| P/E Ratio | $18.01 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $18.52 | $49.86 |
| 52 Week High | $26.38 | $122.20 |
| Indicator | KRG | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 48.03 |
| Support Level | $21.87 | $84.39 |
| Resistance Level | $26.29 | $97.19 |
| Average True Range (ATR) | 0.43 | 5.37 |
| MACD | -0.05 | 0.77 |
| Stochastic Oscillator | 32.34 | 48.67 |
Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.